Real world data show multiple myeloma survival varies by treatment line and autologous stem cell transplant status. Read more ...

Three years after the first FDA approval of CAR-T cell therapy, patients with multiple myeloma are starting to see the therapy emerge in earlier lines. An innovative and groundbreaking cancer ...

A team of scientists have developed a new method that enables them to make precise edits in multiple locations within a cell -- all at once. Using molecules called retrons, they created a tool that ...

In an interview with Targeted Oncology, George Mulligan, PhD, discussed the key takeaways from analysis of the Immune Atlas ...

Study suggests CD4+ T cells mediate these immune-related toxicities ...

Advances in MM management have improved survival, but challenges remain for patients progressing after three therapy lines. New therapies like CAR T-cell and bispecific antibodies require integration ...

Johnson & Johnson announces positive results from phase 3 MajesTEC-9 study of Tecvayli in patients with multiple myeloma ...